Ferric Oxyhydroxide

Summary

Ferric Oxyhydroxide (CHEMBL4802224) is an approved small molecule (ATC V03AE05); indicated across 4 conditions including hyperphosphatemia and chronic kidney disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V03AE05
• Indications: 4 conditions
• Clinical trials: 30

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4802224
Name	Ferric Oxyhydroxide
Type	Small molecule
Max phase	4
ATC	V03AE05

Also known as: Dexferrum, Ferric hydroxide, Ferric oxyhydroxide, Ferrite yellow 2939, Ferrlecit, Infed, Iron dextran, PA-21, PA21, Proferdex, Sucroferric oxyhydroxide, Velphoro

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hyperphosphatemia	4	MONDO:0000328	HP:0002905
chronic kidney disease	4	MONDO:0005300	EFO:0003884

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 30.

Phase distribution

Phase	Trials
PHASE3	11
PHASE1	7
PHASE2	6
PHASE4	4
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00593619	PHASE4	SUSPENDED	Trial Comparing the Safety of Two Different Intravenous Iron Formulations
NCT02390921	PHASE4	COMPLETED	The Use of Liposomated Iron After Bariatric Surgery in Patients That Are Receiving Parentheral Therapy With Iron
NCT03438227	PHASE4	COMPLETED	Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial
NCT05047211	PHASE4	COMPLETED	Intravenous Iron vs. Oral Iron Supplementation for Postpartum Anemia
NCT00145652	PHASE3	COMPLETED	Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders.
NCT00236938	PHASE3	COMPLETED	Efficacy and Safety of Venofer (Iron Sucrose Injection USP) in Patients Receiving Peritoneal Dialysis
NCT00236977	PHASE3	COMPLETED	Comparison of Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia
NCT00704028	PHASE3	COMPLETED	Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia
NCT01833494	PHASE3	COMPLETED	A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
NCT01850602	PHASE3	COMPLETED	A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
NCT01850641	PHASE3	COMPLETED	A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia
NCT01852682	PHASE3	COMPLETED	A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia
NCT02688764	PHASE3	TERMINATED	A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia
NCT03212781	PHASE3	COMPLETED	Iron Dextran Versus Oral Iron for Treating Iron Deficiency Anemia in Pregnant Women
NCT03644264	PHASE3	COMPLETED	PA21 Safety and Efficacy in Adult Chinese Subjects
NCT05800600	PHASE2	RECRUITING	Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy
NCT00721188	PHASE2	COMPLETED	Iron Sucrose in Non-Dialysis Dependent (NDD-CKD) Pediatric Patients
NCT01290315	PHASE2	COMPLETED	Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women
NCT01521494	PHASE2	COMPLETED	PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia
NCT05167734	PHASE2	COMPLETED	Practical Anemia Bundle for SusTained Blood Recovery
NCT05960227	PHASE2	COMPLETED	Effect of Intravenous Iron Repletion on Renal Function in Patients With Iron Deficiency and Acute Kidney Injury
NCT01324752	PHASE1	COMPLETED	A Drug-Drug Interaction Study of Losartan and PA21
NCT01438359	PHASE1	COMPLETED	A Drug-Drug Interaction Study of Furosemide and PA21
NCT01452906	PHASE1	COMPLETED	A Drug-Drug Interaction Study of Omeprazole and PA21
NCT01477411	PHASE1	COMPLETED	A Drug-Drug Interaction Study of Digoxin and PA21
NCT01477424	PHASE1	COMPLETED	A Drug-Drug Interaction Study of Warfarin and PA21
NCT03093883	PHASE1	COMPLETED	Bioequivalence Study Comparing Single Dose of Ferrinemia® Injection With a Single Dose of Venofer® Injection in Healthy Male Volunteers
NCT04155814	PHASE1	COMPLETED	Bioequivalence Study Assessing Iron Sucrose or Venofer® in Healthy Adult Subjects
NCT02687594	Not specified	COMPLETED	Non-interventional Study to Investigate the Short and Long Term Real-life Safety, Effectiveness, and Adherence of Velphoro® in Patients With Hyperphosphataemia Undergoing Haemodialysis (HD) or Peritoneal Dialysis (PD)
NCT03409757	Not specified	TERMINATED	Velphoro and Impact on the Oral Cavity and Gut Microbiome

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).